Description: Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.
Home Page: www.pharmicell.com
Ssangbong Building
Seoul,
South Korea
Phone:
82 2 3496 0114
Officers
| Name | Title |
|---|---|
| Hyun-Soo Kim | Chief Exec. Officer and Inside Director |
| Mr. Shi-Young Jang | Sr. Managing Director |
| Mr. Yongman Kim | Sr. Managing Director |
| Woon-Sung Baek | Sr. Managing Director |
| Yong-Hyun Nam | Exec. Officer |
| Min-Seok Seo | Exec. Officer |
| Jin-Gyoon Gwak | Exec. Officer |
Exchange: KO
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.112 |
| Price-to-Sales TTM: | 29.9459 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |